SAN DIEGO, Feb. 2 /PRNewswire/ -- MediVas, LLC, a leading developer of amino acid based bioabsorbable polymers used for drug and biologic delivery, announced today the appointment of Dr. Antonella Vitiello as the Director of Immunology. Prior to joining MediVas, Dr. Vitiello worked at Johnson and Johnson Pharmaceutical Research & Development where she developed a novel procedure for the in-vitro induction of primary cytotoxic T lymphocytes. Prior to her work at JNJ, Dr. Vitiello was the project leader at Cytel Corporation responsible for the development of the first peptide based vaccine to demonstrate efficacy in the induction of cytotoxic T lymphocytes in a Phase I clinical trial. Dr. Vitiello completed her post-doctoral training at the Scripps Research Institute.
Dr. Vitiello will be heading up MediVas' clinical development of its polymer based subunit vaccine delivery formulations. MediVas' infectious disease and immunology platforms include rapid response formulations for next generation preventative vaccines. The Company's lead preventative vaccine program represents a novel process to develop and manufacture vaccines for both seasonal and pandemic influenza. In addition, the Company is also developing therapeutic vaccines with a lead program targeted against cervical cancer.
"With the appointment of Dr. Vitiello, we continue to advance our capabilities in developing important next-generation biocompatible drug delivery solutions," said Kenneth Carpenter, President and CEO of MediVas. "We are confident in our ability to create innovative new drug delivery technologies across multiple therapeutic areas."
About MediVas:
MediVas, LLC, headquartered in San Diego, CA, is a leading developer of next-generation, bioabsorbable drug and biologic delivery platforms. Having completed its first human clinical trials, MediVas is building alliances with companies that utilize its proprietary biopolymer technology for preventative and therapeutic vaccines and a wide variety of drug & biologic drug delivery applications. MediVas' biopolymer technology enables local or systemic delivery of therapeutic peptides, whole proteins, siRNAs, DNA, and other traditionally difficult to deliver compounds.
For more information about MediVas, please visit http://www.medivas.com. MediVas Corporate Contact: Joseph Dowling 858-622-2005
MediVas, LLCCONTACT: Joseph Dowling of MediVas, LLC, +1-858-622-2005
Web site: http://www.medivas.com//
